- Home
- REFR vs CUE Comparison
REFR vs CUE Comparison
Compare REFR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- CUE
- Stock Information
- Founded
- REFR 1965
- CUE 2014
- Country
- REFR United States
- CUE United States
- Employees
- REFR N/A
- CUE N/A
- Industry
- REFR Multi-Sector Companies
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- REFR Miscellaneous
- CUE Health Care
- Exchange
- REFR Nasdaq
- CUE Nasdaq
- Market Cap
- REFR 56.9M
- CUE 61.1M
- IPO Year
- REFR N/A
- CUE 2018
- Fundamental
- Price
- REFR $1.75
- CUE $0.72
- Analyst Decision
- REFR
- CUE Strong Buy
- Analyst Count
- REFR 0
- CUE 2
- Target Price
- REFR N/A
- CUE $3.00
- AVG Volume (30 Days)
- REFR 131.8K
- CUE 268.4K
- Earning Date
- REFR 11-06-2025
- CUE 11-12-2025
- Dividend Yield
- REFR N/A
- CUE N/A
- EPS Growth
- REFR N/A
- CUE N/A
- EPS
- REFR N/A
- CUE N/A
- Revenue
- REFR $1,222,239.00
- CUE $8,286,000.00
- Revenue This Year
- REFR N/A
- CUE N/A
- Revenue Next Year
- REFR N/A
- CUE N/A
- P/E Ratio
- REFR N/A
- CUE N/A
- Revenue Growth
- REFR N/A
- CUE N/A
- 52 Week Low
- REFR $0.93
- CUE $0.54
- 52 Week High
- REFR $2.70
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- REFR 49.15
- CUE 44.43
- Support Level
- REFR $1.60
- CUE $0.68
- Resistance Level
- REFR $2.70
- CUE $0.78
- Average True Range (ATR)
- REFR 0.25
- CUE 0.06
- MACD
- REFR -0.01
- CUE -0.01
- Stochastic Oscillator
- REFR 13.64
- CUE 24.19
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.